Logo wahanariau.com
  2. New jersey

New jersey

Index
Globenewswire

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

Rabu, 11 November 2026 - 21:29:43 Wib
Globenewswire

Physical AI and Manufacturing Company Nemi to Go Public at a $400 Million Pre-Money Equity Value Through Business Combination with BHAV Acquisition Corp

Kamis, 05 November 2026 - 21:33:56 Wib
Globenewswire

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

Senin, 02 November 2026 - 20:59:19 Wib
Globenewswire

BHAV Acquisition Corp II Announces Closing of $100 Million Initial Public Offering

Senin, 02 November 2026 - 19:30:00 Wib
Globenewswire

BHAV Acquisition Corp II Announces Pricing of $100 Million Initial Public Offering

Kamis, 29 Oktober 2026 - 22:45:31 Wib
Globenewswire

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

Selasa, 20 Oktober 2026 - 22:12:48 Wib
Globenewswire

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Rabu, 14 Oktober 2026 - 21:43:48 Wib
Globenewswire

Impulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One Year

Selasa, 13 Oktober 2026 - 06:23:34 Wib
Globenewswire

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Jumat, 09 Oktober 2026 - 22:45:09 Wib
Globenewswire

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Jumat, 02 Oktober 2026 - 21:27:28 Wib
Globenewswire

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Jumat, 02 Oktober 2026 - 21:26:38 Wib
Globenewswire

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Selasa, 29 September 2026 - 22:34:15 Wib
Globenewswire

DALI Lighting Awards 2027 Resmi Membuka Pendaftaran Karya

Jumat, 25 September 2026 - 21:20:36 Wib
Globenewswire

Teva Releases Q3 2026 Aide Memoire

Kamis, 24 September 2026 - 22:18:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Kamis, 24 September 2026 - 22:17:25 Wib
Globenewswire

DALI Lighting Awards 2027 Open for Entries

Rabu, 23 September 2026 - 23:33:58 Wib
Globenewswire

DALI Alliance Mengumumkan Rencana Penyelenggaraan KTT + Pameran Global DALI 27 Perdana

Rabu, 23 September 2026 - 23:31:49 Wib
Globenewswire

DALI Alliance Announces DALI 27 Inaugural Global Summit + Expo

Selasa, 22 September 2026 - 21:04:29 Wib
Globenewswire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Senin, 21 September 2026 - 20:24:09 Wib
Globenewswire

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Senin, 21 September 2026 - 20:23:18 Wib
Globenewswire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Senin, 21 September 2026 - 20:22:15 Wib
Globenewswire

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Rabu, 16 September 2026 - 22:54:54 Wib
Globenewswire

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Senin, 14 September 2026 - 21:28:13 Wib
Globenewswire

Global Insured Catastrophe Losses Now Expected to Average $171 Billion Annually, Verisk Finds

Selasa, 01 September 2026 - 22:28:34 Wib
Globenewswire

Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans

Selasa, 01 September 2026 - 22:17:53 Wib